Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Shares Outstanding for 9 consecutive years, with $69.7 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 0.73% year-over-year to $69.7 million; the TTM value through Mar 2026 reached $69.7 million, up 0.73%, while the annual FY2025 figure was $69.4 million, 0.44% changed from the prior year.
  • Shares Outstanding hit $69.7 million in Q1 2026 for Bicycle Therapeutics, roughly flat from $69.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $69.7 million in Q1 2026 and bottomed at $29.6 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $50.6 million, with a median of $42.6 million recorded in 2024.
  • Year-over-year, Shares Outstanding skyrocketed 125.4% in 2024 and then rose 0.42% in 2025.
  • Bicycle Therapeutics' Shares Outstanding stood at $29.9 million in 2022, then skyrocketed by 42.04% to $42.4 million in 2023, then surged by 62.76% to $69.1 million in 2024, then rose by 0.44% to $69.4 million in 2025, then increased by 0.49% to $69.7 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $69.7 million, $69.4 million, and $69.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.